---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-100550"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-08-26T23:59:59+00:00"
generated_at: "2026-05-31T07:42:01.076386+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences raises ~$3.8M via warrant exercises; issues new warrants

## Summary
- Class D warrant holders exercise 2,548,060 shares at reduced price of $1.50/share, gross proceeds ~$3.8M.
- New Inducement Warrants issued to purchase up to 5,096,120 shares at $1.00/share, exercisable for 5 years.
- Net proceeds to fund GEM-AKI, GEM-CKD, GEM-PSI clinical trials and working capital.
- Roth Capital Partners paid ~$267,546 advisory fee; exercise prices of certain Class C/D warrants adjusted to $1.00.

## SEC filing metadata
- accession: 0000950170-24-100550
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024100550/0000950170-24-100550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024100550/revb-20240821.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-100550
- JSON: https://secwatch.observer/filing/0000950170-24-100550.json
- Plain text: https://secwatch.observer/filing/0000950170-24-100550.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.